Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EONS Poster diplay

3985 - EONS Poster - Systemic Anticancer Therapy Administration Safety


22 Oct 2018


EONS Poster diplay


Cytotoxic Therapy

Tumour Site


Samantha Toland


Annals of Oncology (2018) 29 (suppl_8): viii683-viii688. 10.1093/annonc/mdy276


S. Toland1, A. Simons2

Author affiliations

  • 1 Oncology, Birmingham City University, B31 3PL - Birmingham/GB
  • 2 Birmingham City University, Birmingham City University, B15 3TN - Birmingham city university/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3985


SACT safety in administration and waste disposal Our original article explored the immediate adverse effects experienced by nurses during the administration of systemic anti-cancer therapy (SACT), specifically cytotoxic chemotherapy, and whether closed systems are being used tominimise exposure risk. Many SACT agents are known to be carcinogenic, teratogenic and mutagenic and this has led to concerns relating to the increased number of healthcare workers potentially exposed to these agents.

An anonymous online survey was designed, made up of four questions, to elicit whether adverse effects were experienced by nurses during preparation, administration or following administration of chemotherapy. A total of 46% of respondents stated that they experienced some form of adverse effect either during preparation, administration or following administration of SACT. More formal research is required in this area to explore the relationship between exposure to SACT and perceived adverse effects in healthcare workers administering SACT. As a follow up to this survey, we are going to develop a further survey to elicit healthcare professionals awareness of SACT exposure risk, education / training provision and current practices in relation to SACT administration and waste disposal.


In our original study, a short anonymous online survey was designed made up of four questions to elicit whether adverse effects were experienced by nurses during preparation or administration or following administration of chemotherapy. This was distributed via social media and networking contacts. For our follow-up survey, we will replicate this method, including questions about awareness, education / training and current practice in relation to SACT administration and waste disposal


of the original study were obtained through the questionnaire responses which were analysed and presented using a quantitative approach. The follow up survey will require a mixed methods approach to analysis to elicit greater depth of information from participants.


Following quantitative analysis of our original survey, we concluded that further research was required in this area, hence the need for additional data collection via a further online survey.

Clinical trial identification

Legal entity responsible for the study

Samantha Toland and Alison Simons.


Has not received any funding.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.